Tong Ren Tang Technologies Co. Ltd. (HKG:1666)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 5.02B -21.4% |
| Revenue (ttm) | 7.22B -10.7% |
| Net Income | 440.98M -24.1% |
| EPS | 0.34 -24.1% |
| Shares Out | 1.28B |
| PE Ratio | 11.39 |
| Forward PE | 9.76 |
| Dividend | 0.21 (5.24%) |
| Ex-Dividend Date | Jun 16, 2025 |
| Volume | 780,000 |
| Average Volume | 1,003,560 |
| Open | 3.900 |
| Previous Close | 3.920 |
| Day's Range | 3.900 - 3.960 |
| 52-Week Range | 3.840 - 5.520 |
| Beta | 0.92 |
| RSI | 40.64 |
| Earnings Date | Mar 27, 2026 |
About HKG:1666
Tong Ren Tang Technologies Co. Ltd., together with its subsidiaries, produces and distributes Chinese medicine products in Mainland China and Hong Kong. It operates through The Company; Tong Ren Tang Chinese Medicine; and Others segments. The company also develops, cultivates, processes, and purchases Chinese medicinal raw materials; retails and wholesales Chinese medicine products and healthcare products; and offers ointments, healthcare products, tea drinks, food, foot care products, biological products, western medicine, and cosmetics. In ad... [Read more]
Financial Performance
In 2025, HKG:1666's revenue was 6.48 billion, a decrease of -10.69% compared to the previous year's 7.26 billion. Earnings were 396.28 million, a decrease of -24.06%.
Financial numbers in CNY Financial StatementsNews
Chinese Medicine Firm Seeks Elusive Elixir Of IPO Success
The healthcare services arm of the Tong Ren Tang group enjoys a high-profile TCM brand, but its profit margins lag far behind industry peers Key Takeaways: Tong Ren Tang Healthcare ranks as China's bi...